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Abstract: Background: In the recent years the 2-imino-1,3-thiazine and 2-iminothiazolidine ring systems can be 
found as moieties in biologically relevant compounds, including BACE1 inhibitors, or cannabinoid receptor ago-
nists, while monoterpene-based 2-imino-1,3-thiazines, prepared from chiral 1,3-amino alcohols exhibiting pro-
nounced antiproliferative activity. 
Methods: The antiproliferative activities of the prepared compounds were determined in vitro against a panel of 
human adherent cancer cell lines including HeLa, MCF7 and A431 by MTT assay.  
Results: Starting from pinane-, apopinane- and carane-based  -amino acid derivatives, 1,3-amino alcohols were 
prepared via two-step syntheses. The reactions of the product 1,3-amino alcohols and aryl isothiocyanates yielded 
!-hydroxythioureas, which were transformed to monoterpene-fused 2-imino-1,3-oxazines via base-catalysed ring 
closure. The antiproliferative activities of these 2-imino-1,3-oxazines were examined and the structure–activity 
relationships were studied from the aspects of the type and stereochemistry of the monoterpene ring and the sub-
stituent effects on the 1,3-oxazine ring system. The N-unsubstituted monoterpene-based derivatives exhibited 
considerable antiproliferative activity against a panel of human adherent cancer cell lines (HeLa, MCF7 and 
A431). 
Conclusions: A mild and efficient method has been developed for the synthesis of 2-imino-1,3-oxazines by the 
ring closure of thiourea adducts of 1,3-amino alcohols. The resulting 1,3-oxazines exert marked antiproliferative 
action on a panel of human cancer cell lines. 
Keywords: Monoterpene, asymmetric synthesis, enantiopure chiral templates, 1,3-amino alcohol, 1,3-oxazine, antiproliferative. 
1. INTRODUCTION 
In the past decade, alicyclic 1,3-aminoalcohols have proved to 
be versatile building blocks and applied as useful starting materials 
in stereoselective syntheses of compounds of pharmacological in-
terest, serving as chiral ligands and auxiliaries in enantioselective 
transformations [1-4]. 
Several natural, chiral terpenes, including (+)-pulegone [5-7], 
"- and #-pinene [8-11] and fenchone-camphor [12-14], have been 
found to be excellent sources for the production of various amino 
alcohols, which have been successfully applied in enantioselective 
syntheses [1, 4]. The transformation of enantiomerically pure "-
pinene to  -amino acid derivatives such as 1,3-aminoalcohols was 
recently reported [3, 10, 15, 16], and these synthons have proved to 
be useful chiral auxiliaries in the enantioselective synthesis of sec-
ondary alcohols or pharmacons, e.g. esomeprasol [17-21]. 
Besides their value in enantioselective catalysis, 1,3-
aminoalcohols are good starting materials for the synthesis of vari-
ous heterocyclic ring systems, such as 1,3-oxazines, 1,3-thiazines or 
1,4-oxazepams [2, 22, 23]. The 2-imino-1,3-thiazine and 2-
iminothiazolidine ring systems can be found as moieties in biologi-
cally relevant compounds, including BACE1 inhibitors [24] and 
cannabinoid receptor agonists [25-27]. 
In recent years, novel pathways have been developed for the 
synthesis of monoterpene-based chiral  -lactams and  -amino acid 
derivatives derived from (-)- and (+)-"-pinene, (-)-3-carene, (-)-and 
(+)-apopinene and peryllic acid [3, 10, 15, 16, 28-31]. These 
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amino acid derivatives have been shown to be excellent building 
blocks for the syntheses of compounds with MDR antagonist activ-
ity [29], while some of the amino carboxamide derivatives dis-
played marked KDR and Aurora B kinase inhibitor activities [32]. 
Monoterpene-based 1,3-amino alcohols prepared from the ap-
propriate  -amino acid derivatives are excellent building blocks for 
the synthesis of 2-imino-1,3-thiazines via CDI-promoted ring clo-
sure. The resulting monoterpene-fused 1,3-heterocycles exhibited 
pronounced antiproliferative activity against a panel of human ad-
herent cancer cell lines [33]. 
Since the analogues bearing the 2-imino-1,3-oxazine ring sys-
tem also display noteworthy pharmacological activities [22], e.g. as 
BACE1 inhibitors [34], cannabinoid receptor agonists [35] or an-
timicrobial agents [36], the aim of the present work was to synthe-
size new chiral pinane-, apopinane- and carane-fused 2-imino-1,3-
oxazines, analogues of pharmacologically active 2-imino-1,3-
thiazines, to study their antiproliferative activity on multiple cancer 
cell lines. 
2. MATERIALS AND METHODS  
2.1. General Synthetic Procedures 
1H-NMR spectra were recorded in CDCl3, CD3OD or D2O in a 
5-mm tube with a Bruker Avance DRX 400 spectrometer at 400.13 
MHz (1H) and 100.61 MHz (13C) ["=0 (TMS)]. Chemical shifts are 
expressed in ppm (") relative to TMS as internal reference. J values 
are given in Hz. Microanalyses were performed on a Perkin-Elmer 
2400 elemental analyser. Optical rotations were measured with a 
Perkin-Elmer 341 polarimeter. Melting points were determined on a 
Kofler apparatus and are uncorrected. Chromatographic separations 
were carried out on Merck Kieselgel 60 (230-400 mesh ASTM). 
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Reactions were monitored with Merck Kieselgel 60 F254-precoated 
tlc plates (0.25 mm thickness). IR spectra were recorded with an 
FT-IR spectrometer. 
The enantiomeric purities of the prepared compounds were 
based on the enantiomeric purities of their starting materials, de-
termined by means of GC measurements with direct separation of 
the enantiomers according to literature procedures [15, 16, 28]. 
During the transformations, 1H-NMR spectra indicated the forma-
tion of a single diastereoisomer in each case. 
Compounds 3-8 and thioureas 15a, 15c-e, 16a, 23 and 27-29
were prepared according to literature methods [15, 16, 28, 33, 37, 
38]; all spectroscopic data and physical properties were similar to 
those reported previously. 
2.2. General Procedure for the Preparation of Aminoalcohols 
To a slurry of LiAlH4 (0.93 g, 24.5 mmol) in dry THF (150 ml), 
2.00 g (9.5 mmol) of the appropiate amino ester 3-5 was added 
dropwise at 0 °C. After stirring at room temperature for 1.5 h and 
monitoring the reduction by means of TLC, the mixture was de-
composed with a mixture of THF (10 ml) and H2O (2.0 ml) under 
ice cooling. The inorganic material was filtered off and washed 
with THF (3x75 ml). After drying (Na2SO4) and evaporation, a 
pale-yellow oil was obtained. The hydrochloride salt of the result-
ing aminoalcohol was purified by recrystallization from an 
Et2O/EtOH mixture. 
(1R,2R,3S,5R)-(2-Amino-6,6-dimethylbicyclo[3.1.1]hept-3-
yl)methanol hydrochloride (9). It was synthesized from 3 by the 
general method. The isolated compound was a white solid (1.37 
g,70%). Mp 179-183 °C; ["]D
20 = -16.4 (c 0.5, MeOH); IR = 3123, 
2917, 1529, 1457, 1051 cm-1. 1H-NMR (CDCl3) " (ppm): 0.95 (3H, 
s), 1.15 (1H, d, J = 11.1 Hz), 1.28 (3H, s), 1.44 (1H, dt, J = 4.0, 
14.1 Hz), 1.97-2.03 (1H, m), 2.09-2.18 (2H, m), 2.27-2.34 (1H, m), 
2.59-2.70 (1H, m), 3.73 (2H, ddd, J = 5.0, 11.58, 40.2 Hz), 3.98 
(1H, d, J = 9.6 Hz). 13C-NMR (CDCl3) " (ppm): 19.9 (Me), 25.2 
(CH2), 25.8 (Me), 29.0 (CH2), 30.3 (CH), 38.6 (Cq), 40.0 (CH), 45.0 
(CH), 52.9 (CH), 65.0 (CH2). Anal. Calcd. for C10H20ClNO 
(205.72): C, 58.38; H, 9.80; N, 6.81. Found: C, 58.61; H, 10.11; N, 
6.49. 
(1S,2S,3R,5S)-(2-Amino-6,6-dimethylbicyclo[3.1.1]hept-3-
yl)methanol hydrochloride (12). It was synthesized from 5 using the 
general method. All chemical and physical properties of 12 were 
similar to those of 9. The isolated compound was a white solid 
(1.41 g, 72%). Mp 179-183 °C; ["]D
20 = +13.4 (c 0.5, MeOH). 
Anal. Calcd. for C10H20ClNO (205.72): C, 58.38; H, 9.80; N, 6.81. 
Found: C, 58.59; H, 10.17; N, 6.43. 
(1R,2R,3R,5R)-(2-Amino-6,6-dimethylbicyclo[3.1.1]hept-3-
yl)methanol hydrochloride (13). It was synthesized by the general 
method from 6. The isolated compound was a white solid (1.52 g, 
78%). Mp 199-202 °C; ["]D
20 = -7.9 (c 0.52, MeOH); IR = 3298, 
2905, 1512, 1040 cm-1. 1H-NMR (CDCl3) " (ppm): 0.86 (3H, s), 
1.32 (3H, s), 1.50-1.59 (1H, m), 1.62 (1H, d, J = 10.6 Hz), 2.03-
2.20 (4H, m), 2.28-2.36 (1H, m), 3.63 (1H, d, J = 8.1 Hz), 3.73 (2H, 
ddd, J = 2.5, 5.5, 11.1 Hz). 13C-NMR (CDCl3) " (ppm): 19.1 (Me), 
23.1 (CH2), 26.2 (Me), 26.3 (CH2), 35.1 (CH), 89.7 (CH), 40.0 (Cq),
44.2 (CH), 54.6 (CH), 64.5 (CH2). Anal. Calcd. for C10H20ClNO 
(205.72): C, 58.38; H, 9.80; N, 6.81. Found: C, 58.67; H, 10.08; N, 
6.51. 
(1S,2S,3S,5S)-(2-Amino-6,6-dimethylbicyclo[3.1.1]hept-3-
yl)methanol hydrochloride (14). Its synthesis from 7 was performed 
using the general procedure. All chemical and physical properties 
of 14 were similar to those of 13. The isolated compound was a 
white solid (1.52 g, 78%). Mp 199-202 °C; ["]D
20 = +8.1 (c 0.5, 
MeOH). Anal. Calcd. for C10H20ClNO (205.72): C, 58.38; H, 9.80; 
N, 6.81; Found: C, 58.49; H, 9.71; N, 6.93. 
(1R,2R,3S,5R)-(2-Benzylamino-6,6-dimethylbicyclo[3.1.1]hep-
tan-3-yl)-methanol hydrochloride (10). It was synthesized by the 
general method from 4. The isolated compound was a white solid 
(1.71 g, 61%). Mp 252-253 °C; ["]D
20 = -8.5 (c 0.5, MeOH); IR = 
3177, 2927, 2741, 1597, 1457, 1048 cm-1. 1H-NMR (D2O) " (ppm) 
0.94 (3H, s), 1.23 (1H, d, J = 11.1 Hz), 1.36 (3H, s), 1.44 (1H, dt, J
= 4.0, 14.1 Hz), 2.02-2.23 (2H, m), 2.37-2.55 (3H, m), 2.64-2.75 
(1H, m), 3.74-3.94 (3H, m), 4.23 (1H, d, J = 13.1), 4.44 (1H, d, J = 
13.1 Hz). 13C-NMR (CDCl3) " (ppm): 19.8 (Me), 25.3 (CH2), 25.9 
(Me), 28.8 (CH2), 30.7 (CH), 38.5 (Cq), 39.7 (CH), 41.9 (CH), 49.9 
(CH2), 59.8 (CH), 65.6 (CH2), 129.8 (4xCHar), 130.1 (CHar), 131.5 
(Cq). Anal. Calcd. for C17H26ClNO (295.85): C, 69.02; H, 8.86; N, 
4.73. Found: 68.85; H, 8.67; N, 4.97. 
(1R,2R,3S,5R)-(6,6-Dimethyl-2-methylaminobicyclo[3.1.1]-
heptan-3-yl)-methanol hydrochloride (11). To a slurry of LiAlH4
(2.82 g, 74.32 mmol) in dry THF (150 ml), a THF solution of N-
Boc amino acid 8 (4.78 g, 16.9 mmol, 10 ml) was added dropwise 
at room temperature. After stirring at room temperature for 6 h (the 
reduction was monitored by means of TLC), the mixture was de-
composed with a mixture of THF (30 ml) and H2O (6.0 ml) under 
ice cooling. The inorganic material was filtered off and washed 
with THF (3x50 ml). After drying (Na2SO4) and evaporation of the 
solvent, a pale-yellow oil was obtained. The hydrochloride salt of 
the resulting aminoalcohol was purified by recrystallization from an 
Et2O/EtOH mixture. The isolated compound was a white solid (1.44 
g, 39%). Mp 192-193 °C; ["]D
20 = -15.7 (c 0.5, MeOH); IR = 3308, 
3123, 2916, 2475, 1595, 1458, 1049 cm-1. 1H-NMR (D2O) " (ppm): 
0.99 (3H, s), 1.18 (1H, d, J = 10.6 Hz), 1.35 (3H, s), 1.48-1.55 (1H, 
m), 2.03-2.10 (1H, m), 2.15-2.24 (1H, m), 2.33-2.47 (2H, m), 2.74 
(3H, s), 2.72-280 (1H, m), 3.73-3.91 (3H, m). 13C-NMR (CDCl3) "
(ppm): 20.0 (Me), 25.1 (CH2), 26.1 (Me), 29.2 (CH2), 31.1 (CH), 
32.1 (CH), 38.4 (C), 39.9 (CH), 41.1 (CH), 62.0 (Me), 65.1 (CH2).
Anal. Calcd. for C11H22ClNO (219.14): C, 60.12; H, 10.09; N, 7.20. 
Found: C, 60.33; H, 10.27; N, 6.95. 
2.3. General Procedure for the Synthesis of Thioureas 15-17, 21, 
23 and 25 
These compounds were synthesized by dissolving amino alco-
hols 9-14 (1.62 mmol) and the appropriate isothiocyanates (1.71 
mmol) in toluene (100 mL) and stirring the mixtures at room tem-
perature for 6 h. In the case of N-benzylamino alcohol 10, heating 
at 50 °C for 6 h was applied. The resulting reaction mixtures were 
then evaporated to dryness, filtered and washed with n-hexane. The 
purities of the products were determined by NMR to be >97%. 
(1R,2R,3R,5R)-1-(3-Chlorophenyl)-3-(3-hydroxymethyl-6,6-
dimethylbicyclo[3.1.1]hept-2-yl)thiourea (15b). It was synthesized 
by the general method from 9 and 3-chlorophenyl isothiocyanate. 
The isolated compound was a white solid (0.51 g, 92%). Mp 155-
156 °C; ["]D
20 = +13.0 (c 0.25, MeOH); IR = 3352, 2914, 1536, 
1475, 1306, 691 cm-1. 1H-NMR (CDCl3) " (ppm): 1.00 (3H, s), 1.04 
(1H, d, J = 10.0 Hz), 1.23 (3H, s), 1.66-1.78 (1H, m), 1.89-2.19 
(5H, m), 2.53-2.64 (1H, m), 3.52-2.59 (1H, m), 3.64-3.71 (1H, m), 
5.17 (1H, br s), 7.12 (1H, d, J = 7.5 Hz), 7.20 (1H, d, J = 7.7 Hz), 
7.28 (1H, d, J = 3.3 Hz), 7.31 (1H, t, J = 7.9 Hz), 7.39 (1H, br d, J = 
7.6 Hz), 8.04 (1H, br s). 13C-NMR (CDCl3) " (ppm): 21.2 (Me), 
26.6 (CH2), 26.7 (Me), 30.0 (CH2), 32.4 (CH), 39.4 (Cq), 40.8 (CH), 
46.3 (CH), 57.3 (CH), 64.9 (CH2), 123.2 (CHar), 125.2 (CHar),
127.1 (CHar), 131.2 (CHar), 135.7 (Cq), 137.8 (Cq), 179.9 (C=S). 
Anal. Calcd for C17H23ClN2OS (338.90): C, 60.25; H, 6.84; N, 
8.27; S, 9.46%; Found: C, 60.39; H, 8.10; N, 8.32; S, 9.53%. 
(1R,2R,3R,5R)-1-Ethyl-3-(3-hydroxymethyl-6,6-dimethylbicyclo 
[3.1.1]hept-2-yl)thiourea (15f). It was synthesized by the general 
method from 9 and ethyl isothiocyanate. The isolated compound 
was a white solid (0.37 g, 89%). Mp 158-160 °C; ["]D
20 = +6.0 (c
0.25, MeOH); IR = 3236, 2916, 1568, 1587, 1518, 1265 cm-1. 1H-
NMR (CDCl3) " (ppm): 1.02 (3H, s), 1.19 (1H, d, J = 9.3 Hz), 1.23 
(3H, t, J = 7.3 Hz), 1.25 (3H, s), 1.75 (1H, ddd, J = 2.9, 6.0, 13.3 
Hz), 1.93-1.99 (1H, m), 2.04-2.22 (3H, m), 2.55-2.65 (1H, m), 
3.24-3.40 (2H, m), 3.63 (1H, dd, J = 4.6, 10.8 Hz), 3.74 (1H, dd, J
= 2.8, 10.9 Hz), 5.05 (1H, br s), 5.89 (1H, br s), 6.83 (1H, d, J = 7.9 
Hz). 13C-NMR (CDCl3) " (ppm): 14.4 (Me), 21.2 (Me), 26.8 (Me), 
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26.9 (CH2), 30.2 (CH2), 32.8 (CH), 38.6 (CH2), 39.4 (Cq), 40.8 
(CH), 46.7 (CH), 56.5 (CH), 65.4 (CH2), 181.1 (C=S). Anal. Calcd 
for C13H24N2OS (256.41): C, 60.89; H, 9.43; N, 10.93; S, 12.51%; 
Found: C, 60.97; H, 9.32; N, 11.11; S, 12.61%. 
(1R,2R,3R,5R)-1-Benzyl-1-(3-chlorophenyl)-3-(3-hydroxy-
methyl-6,6-dimethylbicyclo[3.1.1]hept-2-yl)thiourea (16b). It was 
synthesized by the general method from 10 and 3-chlorophenyl 
isothiocyanate. The isolated compound was a white solid (0.59 g, 
85%). Mp 143-145 °C; ["]D
20 = +12.0 (c 0.25, MeOH); IR = 2934, 
1687, 1580, 1223, 763, 723 cm-1. 1H-NMR (CDCl3) " (ppm): 1.10 
(3H, s), 1.25 (3H, s), 1.51 (1H, d, J = 10.3 Hz), 1.76-1.83 (1H, m), 
1.90-2.05 (3H, m), 2.09-2.16 (1H, m), 2.20-2.32 (1H, m), 3.53-3.61 
(1H, m), 3.65-3.69 (1H, m), 3.72 (1H, dd, J = 2.0, 10.6 Hz), 3.86 
(1H, dd, J = 3.0, 10.6 Hz), 4.74-4.91 (2H, m), 7.16 (1H, d, J = 7.6 
Hz), 7.20-7.38 (9H, m). 13C-NMR (CDCl3)   (ppm): 19.9 (Me), 
25.3 (Me), 27.3 (CH2), 27.5 (CH2), 35.6 (CH), 40.0 (Cq), 42.8 (CH), 
45.8 (CH), 49.0 (CH2), 59.6 (CH), 62.1 (CH2), 123.3 (CHar), 123.5 
(CHar), 125.3 (CHar), 125.4 (CHar), 127.0 (CHar), 127.6 (CHar),
131.4 (CHar), 135.6 (Cq), 135.7 (Cq), 137.9 (Cq), 180.7 (C=S). Anal. 
Calcd for C24H29ClN2OS (429.02): C, 67.19; H, 6.81; N, 6.53; S, 
7.47%; Found: C, 67.39; H, 6.60; N, 6.65; S, 7.54%. 
(1R,2R,3R,5R)-1-(3-Hydroxymethyl-6,6-dimethylbicyclo[3.1.1]-
hept-2-yl)-1-methyl-3-phenylthiourea (17a). It was synthesized by 
the general method from 11 and phenyl isothiocyanate. The isolated 
compound was a white solid (0.49 g, 94%). Mp 151-153 °C; ["]D
20
= +90.0 (c 0.25, MeOH); IR = 3272, 2912, 1514, 1341, 691 cm-1.
1H-NMR (CDCl3)   (ppm): 0.96 (3H, s), 1.29 (3H, s), 1.52 (1H, d, J
= 10.2 Hz), 1.72 (1H, dt, J = 3.4, 13.9 Hz), 1.91-1.97 (1H, m), 2.03-
2.17 (3H, m), 2.36-2.44 (1H, m), 2.79-2.92 (1H, m), 3.14 (3H, s), 
3.46-3.58 (1H, m), 3.63-3.73 (1H, m), 5.45 (1H, br s), 7.14 (1H, br 
s), 7.15-7.37 (5H, m). 13C-NMR (CDCl3)   (ppm): 21.1 (Me), 26.8 
(Me), 27.8 (CH2), 29.7 (CH2), 34.4 (CH), 39.9 (CH), 40.8 (Cq), 45.7 
(CH), 11.2 (Me), 67.3 (CH2), 126.0 (CHar), 126.1 (CHar), 129.1 
(CHar), 140.4 (Cq), 183.2 (C=S). Anal. Calcd for C18H26N2OS 
(318.48): C, 67.88; H, 8.23; N, 8.80; S, 10.07%; Found: C, 67.97; 
H, 8.09; N, 8.92; S, 10.31%. 
(1S,2S,3R,5S)-1-(3-Hydroxymethyl-6,6-dimethylbicyclo[3.1.1] 
hept-2-yl)-3-phenylthiourea (21). It was synthesized by the general 
method from 12 and phenyl isothiocyanate. All chemical and 
physical properties of 21 were similar to those of 15a reported in 
the literature [33]. The isolated compound was a white solid (0.47 
g, 95%). Mp 151-154 °C; ["]D
20= -50.0 (c 0.25, MeOH). Anal. 
Calcd for C17H24N2OS (304.45): C, 67.07; H, 7.95; N, 9.20; S, 
10.53%; Found: C, 67.39; H, 8.13; N, 9.01; S, 10.42%. 
(1S,2S,3S,5S)-1-(3-Hydroxymethyl-6,6-dimethylbicyclo[3.1.1] 
hept-2-yl)-3-phenylthiourea (25). It was synthesized by the general 
method from 14 and phenyl isothiocyanate. All chemical and 
physical properties of 25 were similar to those of 23 reported in the 
literature [33]. The isolated compound was a white solid (0.46 g, 
94%). Mp 151-155 °C; ["]D
20 = +18.0 (c 0.25, MeOH). Anal. Calcd 
for C17H24N2OS (304.45): C, 67.07; H, 7.95; N, 9.20; S, 10.53%; 
Found: C, 67.31; H, 7.80; N, 9.30; S, 10.41%. 
2.4. General Procedure for the Preparation of 2-Imino-1,3-
Oxazines 
To the solution of the corresponding thiourea (1.7 mmol of 15-
17, 21, 23 and 25) in dry MeOH (20 ml) MeI (0.58 ml, 9.3 mmol) 
was added in one portion. The reaction mixture was stirred at room 
temperature for 3 h and then evaporated to dryness. The resulting 
semisolid material was dissolved in a 2.5 N methanolic solution of 
KOH (20 ml). The mixture, after stirring for an additional 4 h at 
room temperature, was evaporated to dryness. The remaining crude 
product was dissolved in H2O (30 ml) and extracted with CHCl3
(3x30 ml). The combined organic layer was dried (Na2SO4) and 
evaporated, resulting in white crystalline products, which were 
purified by recrystallization from an n-hexane/EtOAc mixture. As 
an exception, 18f was purified as the hydrochloride salt by recrys-
tallisation from an EtOH/Et2O mixture. 
(1R,2R,7S,9R)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]-
undec-4-ylidene)phenylamine (18a). It was synthesized by the gen-
eral method from 15a. The isolated compound was a white solid 
(0.36 g, 78%). Mp 164-166 °C; ["]D
20 = +32.7 (c 0.5, MeOH); IR = 
2915, 1667, 1587, 1223, 763 cm-1. 1H-NMR (CDCl3) " (ppm): 0.91 
(3H, s), 1.24 (3H, s), 1.34 (1H, d, J = 10.7 Hz), 1.37-1.41 (m, 1H), 
1.92-2.17 (4H, m), 2.45-2.65 (1H, m), 3.86-4.12 (3H, m), 6.95-7.25 
(5H, m). 13C-NMR (CDCl3) " (ppm): 20.8 (Me), 25.9 (CH2), 26.9 
(Me), 28.6 (CH2), 28.7 (CH), 39.4 (Cq), 40.9 (CH), 47.2 (CH), 52.2 
(CH), 71.5 (CH2), 122.6 (CHar), 123.5 (CHar), 129.1 (CHar), 131.6 
(Cq), 151.6 (C=N). Anal. Calcd. for C17H22N2O (270.37): C, 75.52; 
H, 8.20; N, 10.36. Found: C, 75.87; H, 8.25; N, 10.11. 
(1S,2S,7R,9S)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]-
undec-4-ylidene)phenylamine (22). 22 was synthesized by the gen-
eral method from 21. All chemical and physical properties of 22
were similar to those of 21. The isolated compound was a white 
solid (0.36 g, 78%). Mp 164-166 °C; ["]D
20 = -9 (c 0.25, MeOH). 
Anal. Calcd. for C17H22N2O (270.37): C, 75.52; H, 8.20; N, 10.36. 
Found: C, 75.80; H, 8.29; N, 10.09. 
(1R,2R,7R,9R)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]-
undec-4-ylidene)phenylamine (24). It was synthesized by the gen-
eral method from 23. The isolated compound was a white solid 
(0.29 g, 64%). Mp 118-121 °C; ["]D
20 = +77 (c 0.25, MeOH); IR = 
2904, 1666, 1590, 1205, 695 cm-1. 1H-NMR (CDCl3) " (ppm): 0.84 
(3H, s), 1.31 (3H, s), 1.46 (1H, t, J = 12.0 Hz), 1.76 (1H, d, J = 10.6 
Hz), 1.80-1.87 (1H, m), 1.97-2.31 (4H, m), 3.51 (1H, d, J = 9.7 
Hz), 4.18 (1H, dd, J = 12.4, 9.2 Hz), 4.36 (1H, dd, J = 8.7, 5.1 Hz), 
6.86-7.31 (5H, m). 13C-NMR (CDCl3) " (ppm): 20.1 (Me), 24.0 
(CH2), 24.6 (CH2), 28.1 (Me), 33.4 (CH), 41.8 (CH), 42.2 (Cq), 46.6 
(CH), 55.0 (CH), 73.4 (CH2), 119.4 (CHar), 122.2 (CHar), 129.4 
(CHar), 136.5 (Cq), 150.7 (C=N). Anal. Calcd. for C17H22N2O
(270.37): C, 75.52; H, 8.20; N, 10.36; Found: C, 75.68; H, 8.41; N, 
10.56. 
(1S,2S,7S,9S)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]
undec-4-ylidene)phenylamine (26). It was synthesized by the gen-
eral method from 25. All chemical and physical properties of 26
were similar to those of 24. The isolated compound was a white 
solid (0.30 g, 65%). Mp 118-121 °C; ["]D
20 = -76 (c 0.25, MeOH); 
IR = 2904, 1666, 1590, 1205, 695 cm-1. Anal. Calcd. for C17H22N2O
(270.37): C, 75.52; H, 8.20; N, 10.36; Found: C, 75.60; H, 8.35; N, 
10.49. 
(1R,2R,7S,9R)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]-
undec-4-ylidene)-(3-chlorophenyl)amine (18b). It was synthesized 
by a general method from 15b. The isolated compound was a white 
solid (0.26 g, 51%). Mp 157-160 °C; ["]D
20 = +4 (c 0.25, MeOH); 
IR = 2904, 1670, 1584, 1219, 781 cm-1. 1H-NMR (CDCl3) " (ppm): 
0.89 (3H, s), 1.18 (3H, s), 1.32 (1H, d, J = 10.7 Hz), 1.33-1.45 (m, 
1H), 1.72-1.81 (1H, m), 1.90-1.99 (1H, m), 2.01-2.18 (2H, m), 
2.49-2.65 (1H, m), 3.74-4.12 (3H, m), 6.87 (1H, d, J = 7.3 Hz), 
6.93 (1H, d, J = 7.3 Hz), 7.03 (1H, s), 7.14 (1H, t, J = 7.5 Hz). 13C-
NMR (CDCl3)   (ppm): 20.4 (Me), 25.6 (Me), 26.6 (CH2), 28.3 
(CH), 28.4 (CH2), 39.1 (Cq), 40.6 (CH), 46.8 (CH), 51.8 (CH), 71.4 
(CH2), 122.0 (CHar), 122.3 (CHar), 123.9 (CHar), 127.8 (Cq), 129.7 
(CHar), 141.4 (Cq), 153.7 (C=N). Anal. Calcd. for C17H21ClN2O
(304.81): C, 66.99; H, 6.94; N, 9.19; Found: C, 67.27; H, 6.78; N, 
9.35. 
(1R,2R,7S,9R)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]
undec-4-ylidene)-(4-methylphenyl)amine (18c). It was synthesized 
by the general method from 15c. The isolated compound was a 
white solid (0.32 g, 67%). Mp 188-189 °C; ["]D
20 = +8 (c 0.25, 
MeOH); IR = 2902, 1684, 1509, 1223 cm-1. 1H-NMR (CDCl3) "
(ppm): 0.90 (3H, s), 1.22 (3H, s), 1.34 (1H, d, J = 10.7 Hz), 1.35-
1.48 (1H, m), 1.85-2.19 (4H, m), 2.28 (3H, s), 2.49-2.73 (1H, m), 
3.68-4.10 (3H, m), 6.80-7.10 (4H, m). 13C-NMR (CDCl3)   (ppm): 
20.5 (Me), 20.2 (Me), 25.7 (CH2), 26.7 (Me), 28.4 (CH2), 28.5 
(CH), 39.1 (Cq), 40.7 (CH), 46.9 (CH), 51.9 (CH), 71.3 (CH2),
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123.0 (2xCHar), 129.5 (2xCHar), 131.5 (Cq), 143.4 (Cq), 153.6 
(C=N). Anal. Calcd. for C18H24N2O (284.40): C, 76.02; H, 8.51; N, 
9.85; Found: C, 75.81; H, 8.27; N, 9.56. 
(1R,2R,7S,9R)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]
undec-4-ylidene)-(4-fluorophenyl)amine (18d). It was synthesized 
by the general method from 15d. The isolated compound was a 
white solid (0.28 g, 56%). Mp 224-225 °C; [!]D
20 = +17 (c 0.25, 
MeOH); IR = 2930, 1666, 1505, 1208, 849 cm-1. 1H-NMR (CDCl3) 
" (ppm): 0.92 (3H, s), 1.25 (3H, s), 1.35 (1H, d, J = 10.7 Hz), 1.37-
1.47 (m, 1H), 1.87-2.24 (4H, m), 2.53-2.71 (1H, m), 3.80-4.18 (3H, 
m), 6.87-7.07 (4H, m). 13C-NMR (CDCl3) $ (ppm): 20.5 (Me), 25.7 
(CH2), 26.7 (Me), 28.3 (CH2), 28.5 (CH), 39.2 (Cq), 40.7 (CH), 47.0 
(CH), 52.0 (CH), 71.4 (CH2), 115.4 (d, J =22.5 Hz, 2xCHar), 124.3 
(2xCHar), 142.2 (Cq), 153.6 (Cq), 157.3 (C=N). Anal. Calcd. for 
C17H21FN2O (288.36): C, 70.81; H, 7.34; N, 9.71; Found: C, 71.13; 
H, 7.02; N, 9.56. 
(1R,2R,7S,9R)-(10,10-Dimethyl-5-oxa-3-azatricyclo[7.1.1.0
2,7
]
undec-4-ylidene)-(3-methoxyphenyl)amine(18e). It was synthesized 
by the general method from 15e. The isolated compound was a 
white solid (0.23 g, 44%). Mp 139-140 °C; [!]D
20 = -7 (c 0.25, 
MeOH); IR = 3202, 2904, 1665, 1596, 1263, 1091, 773 cm-1. 1H-
NMR (CDCl3) " (ppm): 0.91 (3H, s), 1.23 (3H, s), 1.34 (1H, d, J = 
10.7 Hz), 1.34-1.47 (m, 1H), 1.76-2.20 (4H, m), 2.51-2.74 (1H, m), 
3.77 (3H, s), 3.81-4.20 (3H, m), 6.45-6.73 (3H, m), 7.09-7.22 (1H, 
m). 13C-NMR (CDCl3) $ (ppm): 20.5 (Me), 25.7 (CH2), 26.7 (Me), 
28.4 (CH2), 28.5 (Me), 39.1 (Cq), 40.7 (CH), 47.0 (CH), 51.9 (CH), 
55.5 (CH), 71.3 (CH2), 108.0 (CHar), 109.0 (CHar), 115.8 (CHar), 
129.4 (CHar), 135.2 (Cq), 141.4 (Cq), 154.2 (C=N). Anal. Calcd. for 
C18H24N2O2 (300.40): C, 71.97; H, 8.05; N, 9.33; Found: C, 71.81; 
H, 8.39; N, 9.31. 
(1R,2R,7S,9R)-Ethyl-(10,10-dimethyl-5-oxa-3-azatricyclo[7.1. 
1.0
2,7
]undec-4-ylidene)amine hydrochloride (18f). It was synthe-
sized by the general method from 15f. The prepared crude product 
was purified as the hydrochloride salt with recrystallization from an 
Et2O/EtOH mixture. The isolated compound was a white solid (0.24 
g, 54%). Mp 180-183 °C; [!]D
20 = +6 (c 0.25, MeOH); IR = 2911, 
1690, 1589 cm-1. 1H-NMR (two rotamers, CDCl3) " (ppm): 1.00 
(3H, br s), 1.24 (3H, t, J = 7.1 Hz), 1.34 (3H, br s), 2.03-2.36 (5H, 
m), 2.83-2.99 (1H, m), 3.25-3.45 (2H, m), 3.99-4.60 (3H, m). 13C-
NMR (two rotamers, CDCl3) $ (ppm): 13.4 (Me), 14.6 (Me), 19.7 
(Me), 24.6 (CH2), 26.1 (CH), 26.3 (CH), 27.5 (CH2), 27.9 (CH2), 
36.5 (CH2), 39.1 (Cq), 40.2 (CH), 45.6 (CH), 51.7 (CH), 52.2 (CH), 
72.2 (CH2), 72.7 (CH2), 154.1 (C=N). Anal. Calcd. for 
C13H23ClN2O (258.79): C, 60.33; H, 8.96; N, 10.82; Found: C, 
60.57; H, 8.71; N, 10.97. 
(1R,2R,7S,9R)-(3-Benzyl-10,10-dimethyl-5-oxa-3-azatricyclo[7. 
1.1.0
2,7
]undec-4-ylidene)phenylamine (19a). 19a was synthesized 
by the general method from 16a. The isolated compound was a 
white solid (0.22 g, 36%). Mp 105-108 °C; [!]D
20 = -35 (c 0.25, 
MeOH); IR = 2940, 2918, 2860, 1630, 1579, 1264, 1098, 993, 693. 
1H-NMR (CDCl3) $ (ppm): 0.84 (3H, s), 1.25 (3H, s), 1.32 (1H, d, J 
= 11.1 Hz), 1.72-1.78 (1H, m), 1.91-1.96 (1H, m), 2.12-2.23 (2H, 
m), 2.32-2.37 (1H, m), 2.63-2.73 (1H, m), 3.69-3.73 (1H, m), 3.83 
(1H, dd, J = 3.0, 10.6 Hz), 4.08 (1H, d, J = 15.1 Hz), 4.15 (1H, dd, 
J = 4.5, 10.6 Hz), 5.13 (1H, d, J = 15.1 Hz), 6.90-6.98 (3H, m), 
7.19-7.38 (7H, m). 13C-NMR (CDCl3) $ (ppm): 21.0 (Me), 27.0 
(CH2), 27.6 (Me), 30.0 (CH), 32.0 (CH2), 39.8 (Cq), 40.8 (CH), 44.7 
(CH), 50.3 (CH2), 57.1 (CH), 70.1 (CH2), 122.3 (CHar), 124.1 
(CHar), 127.7 (CHar), 128.6 (CHar), 129.0 (CHar), 139.1 (Cq), 149.0 
(Cq), 154.3 (C=N). Anal. Calcd. for C24H28N2O (360.22): C, 79.96; 
H, 7.83; N, 7.77. Found: C, 79.83; H, 8.01; N, 7.52. 
(1R,2R,7S,9R)-(3-Benzyl-10,10-dimethyl-5-oxa-3-azatricyclo[7. 
1.1.0
2,7
]undec-4-ylidene)-3-chlorophenylamine (19b). It was syn-
thesized by the general method from 16b. The isolated compound 
was a white solid (0.26 g, 39%). Mp 95-97 °C; [!]D
20 = -64 ( 0.25, 
MeOH); IR = 2988, 2925, 2364, 1635, 1585, 1239, 773. 1H-NMR 
(CDCl3) $ (ppm): 0.85 (3H, s), 1.22-1.29 (4H, m), 1.76 (1H, ddd, J 
= 2.5, 5.0, 13.6 Hz), 1.92-1.98 (1H, m), 2.13-2.23 (2H, m), 2.34 
(1H, q, J = 5.5, 8.6 Hz), 2.65-2.75 (1H, m,), 3.72 (1H, dd, J = 2.0, 
10.6 Hz), 3.86 (1H, dd, J = 3.0, 10.6 Hz), 4.08 (1H, d, J = 15.1 Hz), 
4.15 (1H, dd, J = 4.5, 10.6 Hz), 5.10 (1H, d, J = 15.1 Hz), 6.80 (1H, 
d, J = 8.1 Hz), 6.87-6.96 (2H, m), 7.12 (1H, t, J = 8.1 Hz), 7.23-
7.37 (5H, m). 13C-NMR (CDCl3) $ (ppm): 21.0 (Me), 27.0 (CH2), 
27.6 (Me), 29.8 (CH), 32.0 (CH2), 39.8 (Cq), 40.8 (CH), 44.7 (CH), 
50.4 (CH2), 57.2 (CH), 70.2 (CH2), 122.2 (CHar), 122.5 (CHar), 
124.2 (CHar), 127.8 (CHar), 128.5 (CHar), 129.1 (CHar), 129.9 
(CHar), 134.4 (CCl), 138.8 (Cq), 150.4 (Cq), 154.7 (C=N). Anal. 
Calcd. for C24H27ClN2O (394.18): C, 72.99; H, 6.89; N, 7.09; 
Found: C, 73.21; H, 6.55; N, 7.17. 
(1R,2R,7S,9R)-(3-Methyl-10,10-dimethyl-5-oxa-3-azatricyclo 
[7.1.1.0
2,7
]undec-4-ylidene)phenylamine (20a). 20 was synthesized 
by the general method from 17a. The isolated compound was a 
white solid (0.26 g, 54%). Mp 89-91 °C; [!]D
20 = -168 (c 0.25, 
MeOH); IR = 3062, 2948, 2870, 1924, 1636, 1584, 1056, 750, 693. 
1H-NMR (CDCl3) $ (ppm): 0.96 (3H, s), 1.21 (1H, d, J = 10.6 Hz), 
1.28 (3H, s), 1.65-1.73 (1H, m), 1.93-1.97 (1H, m), 2.11-2.21 (2H, 
m), 2.35 (1H, q, J = 5.5, 9.1 Hz), 2.67-2.76 (1H, m), 2.88 (3H, s), 
3.70 (1H, ddd, J = 1.5, 3.5, 10.6 Hz), 3.81 (1H, dd, J = 4.0, 10.6 
Hz), 4.08 (1H, dd, J = 4.5, 10.6 Hz), 6.90-6.96 (3H, m), 7.19-7.25 
(2H, m). 13C-NMR (CDCl3) $ (ppm): 21.1 (Me), 26.6 (CH2), 27.7 
(Me), 29.8 (CH), 31.7 (CH2), 36.0 (CH), 39.6 (Cq), 40.9 (CH), 44.7 
(CH), 60.1 (Me), 70.0 (CH2), 122.2 (CHar), 124.1 (CHar), 129.0 
(CHar), 149.2 (Cq), 154.7 (C=N). Anal. Calcd. for C18H24N2O 
(284.19): C, 76.02; H, 8.51; N, 9.85. Found: C, 75.67; H, 8.40; N, 
10.03. 
2.5. Determination of Antiproliferative Activities 
The antiproliferative activities of the prepared compounds were 
determined in vitro against a panel of human adherent cancer cell 
lines including HeLa (cervix adenocarcinoma), MCF7 (breast ade-
nocarcinoma) and A431 (squamous carcinoma). All cell lines were 
purchased from the European Collection of Cell Cultures (ECCAC, 
Salisbury, UK). The cells were maintained in minimal essential 
medium (Lonza Ltd, Basel, Switzerland) supplemented with 10% 
foetal bovine serum, 1% non-essential amino acids and an antibi-
otic-antimycotic mixture. Near-confluent cancer cells were seeded 
onto a 96-well microplate (5000 cells/well) and, after overnight 
standing, new medium (200 &L) containing the tested compound at 
10 and 30 "M was added. After incubation for 72 h at 37 ºC in 
humidified air containing 5% CO2, the viability of the cells was 
determined by the addition of 5 mg/mL 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide (MTT) solution. During a 4-h 
contact period, the MTT was converted by intact mitochondrial 
reductase and the precipitated formazan crystals were dissolved in 
100 &L DMSO. Finally, the reduced MTT was assayed at 545 nm, 
using a microplate reader; wells with untreated cells were utilized 
as controls [40]. When compounds elicited substantial growth inhi-
bition at 30 "M (at least 40%), the assays were repeated with a set 
of dilutions, sigmoidal dose-response curves were fitted to the de-
termined results and the IC50 values were calculated by means of 
GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA). 
All in vitro experiments were carried out on two microplates with at 
least five parallel wells. Stock solutions of the tested substances (10 
mM) were prepared in DMSO. The highest DMSO content of the 
medium (0.3%) did not have any substantial effect on cell prolifera-
tion. Cisplatin (Ebewe Pharma GmbH, Unterach, Austria) was used 
as reference agent. 
3. RESULTS AND DISCUSSION 
3.1. Synthesis of Alicyclic and Monoterpene-Based 1,3-
Aminoalcohols 
The synthetic routes applied for the preparation of 1,3-
aminoalcohols 9-14 are presented in Scheme 1. The corresponding 
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"-lactams were prepared by the stereoselective cycloaddition of 
chlorosulfonyl isocyanate to (1S,5S)- and (1R,5R)-apopinene (1, 2),
followed by ring opening using literature methods, which resulted 
in the formation of cis-fused "-amino esters 3 and 5. Under alkaline 
conditions, the cis-amino esters underwent fast and complete iso-
merization at the carboxylic function, furnishing trans-amino esters 
6 and 7 in excellent yields [28]. Reduction of 3 and 5-7 with 
LiAlH4 led to primary aminoalcohols 9 and 12-14 (Scheme 1). N-
Benzyl derivative 10 and N-methyl derivative 11, respectively, 
were prepared by LiAlH4 reduction of N-benzylamino ester 4 and 
N-Boc amino acid 8 [29, 37]. 
3.2. Synthesis of 2-Imino-1,3-Oxazine Derivatives 
The intermediate thiourea adducts 15-17 were prepared in good 
to excellent yields [33] by the reaction of the appropriate aryl 
isothiocyanates or ethyl isothiocyanate and 1,3-aminoalcohols 9-11.
Methyl iodide treatment of thioureas 15-17 gave thioether interme-
diates. These were then transformed, without isolation, to 2-imino-
1,3-oxazine derivatives 18-20 by KOH-promoted methyl mercaptan 
elimination under mild conditions [38, 39] (Scheme 2). 
To study the influence of the chiral ring system on pharmacol-
ogical activity, all enantiomers and diastereoisomers of 2-
phenylimino-1,3-oxazines (18a, 22, 24 and 26), were prepared suc-
cessfully according to the general pathway (Scheme 3). 
To collect more information on structure-activity relationships, 
two further monoterpene-based 2-phenylimino-1,3-oxazines (27
and 28) and a cyclohexane analogue (29) were prepared according 
to the literature (27: [15], 28: [16], 29: [38], Fig. 1). 
3.3. Antiproliferative Activities 
The prepared 2-imino-1,3-oxazines were subjected to in vitro  
pharmacological studies in order to characterize their antiprolifera- 
tive actions on a panel of human adherent cancer cell lines. The  
results of the viability assays are presented in Table 1. The substitu- 
ents  of  the  2-imino  function have a crucial impact on the activity 
1, 3, 4, 6, 9-11, 13
3, 4, 9-11: 2R,3S; 5, 12: 2S,3R; 6, 13: 2R,3R; 7, 14: 2S,3S;
3, 5, 9, 12: R1 = H; 4, 10: R1 = CH2Ph; 11: R1 = Me
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COOEt
1, 2
3-5
9-12
NH2
COOEt
NHR1 NH2
OH OH
6, 7
13,14
O
R1= H
NHBoc
COOH
8
2, 5, 7, 12, 14
1 2
35
2
3
i i
i
Scheme 1. Synthesis of starting material 1,3-amino alcohols 9-14: (i) 3 equiv. LiAlH4, THF, rt, 1.5-6 h, yield: 39-78%. 
i
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9, 15a-f, 18a-f: R1 = H;  10, 16a,b, 19a,b: R1 = CH2Ph;
11, 17a, 20a : R1 = Me
a: R2 = Ph; b: R2 = 3-ClC6H4; c: R
2 = 4-MeC6H4;
d: R2 = 4-FC6H4; e: R2 = 3-MeOC6H4; f: R2 = Et
N
O
N
R2
R1
S Me
H
ii
1
2
79
18a-f, 19a,b, 20a
Scheme 2. Synthesis of 2-imino-1,3-oxazines 18-20: (i) 1.05 equiv. R2NCS, toluene, rt, yield: 85-95%; (ii) MeI/MeOH, rt, 3 h; (iii) 2.5 N KOH/MeOH, rt, 4 h, 
yield: 36-67%. 
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Scheme 3. Synthesis of enantio- and diastereomeric oxazines: (i) 1.05 equiv. R2NCS, toluene, rt, yield: 95%; (ii) MeI/MeOH, rt, 3 h, (iii) 2.5 N KOH/MeOH, 
rt, 4 h, yield: 64-78%. 
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Fig. (1). Analogue monoterpene- and cyclohexane-fused 2-phenylimino-1,3-oxazines 27-29.
Table 1. Antiproliferative effects of 2-imino-1,3-oxazines 18-29 on human cancer cell lines. 
Growth Inhibition, % ± SEM
a
[Calculated IC50 Value ("M)]
b
HeLa A431 MCF7 
18a 10 "M 45.15 ± 1.48 48.18 ± 2.76 45.83 ± 2.07 
30 "M
70.10 + 0.95 
[12.26] 
81.34 ± 0.66 
[10.47] 
74.35 ± 1.17 
[11.35] 
18b 10 "M 67.37 ± 2.42 82.97 ± 0.53 51.83 ± 2.96 
30 "M
96.45 ± 0.29 
[8.75] 
95.57 ± 0.45 
[5.48] 
93.76 ± 1.33 
[9.73] 
18c 10 "M 52.36 ± 1.69 58.30 ± 1.38 40.68 ± 2.77 
30 "M
79.23 ± 1.50 
[9.38] 
95.14 ± 0.73 
[8.88] 
95.40 ± 1.80 
[10.89] 
18d 10 "M 32.75 ± 1.48 22.20 ± 1.17 21.29 ± 2.56 
30 "M 55.94 ± 2.44 54.92 ± 1.95 50.46 ± 2.58 
18e 10 "M 46.72 ± 0.97 33.98 ± 2.13 20.63 ± 2.86 
30 "M
79.92 ± 1.69 
[11.26] 
92.61 ± 0.16 66.65 ± 1.84 
18f 10 "M - - - 
30 "M 26.02 ± 2.87 - - 
19a 10 "M 20.70 ± 1.59 - - 
30 "M 43.91 ± 2.13 37.67 ± 2.93 - 
19b 10 "M - 30.34 ± 1.75 - 
30 "M - 35.96 ± 2.26 - 
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Table 1. contd… 
Growth Inhibition, % ± SEM
a
[Calculated IC50 Value ("M)]
b
HeLa A431 MCF7 
20a 10 "M - - - 
30 "M 39.34 ± 2.85 35.23 ± 2.31 - 
22 10 "M 55.81 ± 2.05 56.77 ± 1.20 64.96 ± 2.39 
30 "M
78.40 ± 1.54 
[7.44] 
87.16 ± 0.53 
[8.09] 
78.85 ± 2.24 
[5.03] 
24 10 "M 43.30 ± 1.29 38.08 ± 1.41 56.23 ± 1.78 
30 "M
69.59 ± 0.69 
[16.04] 
87.11 ± 0.46 75.43 ± 2.79 
[7.79] 
26 10 "M
30 "M
50.60 ± 2.33 
68.90 ± 2.11 
[10.73] 
32.73 ± 2.23 
85.24 ± 1.12 
54.55 ± 2.31 
79.23 ± 1.27 
[8.49] 
27 10 "M
30 "M
45.10 ± 0.89 
69.74 ± 1.89 
[13.42] 
32.87 ± 2.99 
92.65 ± 0.68 
42.58 ± 2.92 
94.09 ± 0.98 
[11.15] 
28 10 "M
30 "M
-
81.27 ± 1.50 
-
90.30 ± 1.14 
39.10 ± 2.34 
85.95 ± 0.83 
29 10 "M
30 "M
-
34.31 ± 2.94 
-
-
-
-
Cisplatin 10 "M 42.61 ± 2.33 88.54 ± 0.50 53.03 ± 2.29 
 30 "M
99.93 ± 0.26 
[12.43] 
90.18 ± 1.78 
[2.84] 
86.90 ± 1.24 
[9.63] 
a Substances eliciting less than 20% inhibition of cell proliferation were regarded as ineffective and the results are not presented. 
b The concentration at which 50% inhibition of cell proliferation is exhibited.
of the molecules: aromatic substituents are favored (18a-e), and 
substitution of the aryl group has a limited and inconsequential 
impact on the efficacy, although the m-chlorophenyl (18b) group 
seems to be the most efficient. Without an aromatic function, the 
activity is negligible (18f). N-Benzyl (19a,b) or N-methyl (20a)
substitution of the oxazine ring at position 3 resulted in a pro-
nounced decrease in activity. Since no substantial differences were 
observed between the effects of 18a and 22-26, the configuration of 
C-3 (cis or trans ring fusion for both enantiomers, Schemes 2 and 
3) also appears to be irrelevant. Compounds with analogous 
monoterpene ring systems (27 and 28) have similar antiproliferative 
actions. Replacing the monoterpene ring system with cyclohexane 
(29) led to ineffective congeners, demonstrating that the bicyclic 
monoterpene ring as a pharmacophore part of the present molecules 
is essential for the design and synthesis of novel antiproliferative 
agents. 
CONCLUSION 
In conclusion, we have developed a mild and efficient method 
for the synthesis of 2-imino-1,3-oxazines by the ring closure of 
thiourea adducts of 1,3-aminoalcohols in the presence of MeI fol-
lowed by KOH treatment. The resulting 1,3-oxazines exert marked 
antiproliferative action on a panel of human cancer cell lines. The 
in vitro pharmacological studies have clearly shown that the lipo-
philic monoterpene ring system and the 2-arylimino function are 
essential, while N-substitution on the 1,3-oxazine ring decreases the 
activity. The stereochemistry of the 1,3-oxazines has no influence 
on the antiproliferative effect. 
LIST OF ABBREVIATIONS 
BACE1 = beta-secretase 1 
MDR = multiple drug resistance 
KDR = kinase insert domain receptor 
THF = tetrahydrofurane 
TLC = thin layer chromatography 
CDI = 1,1’-carbonyldiimidzole 
MCF7 = breast adenocarcinoma 
A431 = squamous carcinoma 
HeLa = cervix adenocarcinoma 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide 
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